Trade Summary

Yesterday, Callos Andrew, serving as EVP, Chief Commercial Officer at Cytokinetics Inc (CYTK), sold 11,333 shares at $77.25 per share, for a total transaction value of $875,474.00. Following this transaction, Callos Andrew now holds 58,555 shares of CYTK.

This sale represents a 16.00% decrease in Callos Andrew's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, May 5, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, May 5, 2026, meaning the disclosure happened on the same day as the trade.

Cytokinetics Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.